Louisiana State Employees Retirement System grew its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) by 14.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,000 shares of the company’s stock after purchasing an additional 1,600 shares during the period. Louisiana State Employees Retirement System’s holdings in iTeos Therapeutics were worth $172,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. increased its holdings in iTeos Therapeutics by 16.0% during the third quarter. BlackRock Inc. now owns 4,317,157 shares of the company’s stock worth $82,241,000 after buying an additional 595,920 shares during the last quarter. State Street Corp increased its holdings in iTeos Therapeutics by 44.8% during the second quarter. State Street Corp now owns 2,478,332 shares of the company’s stock worth $51,054,000 after buying an additional 766,441 shares during the last quarter. Vanguard Group Inc. increased its holdings in iTeos Therapeutics by 7.5% during the third quarter. Vanguard Group Inc. now owns 1,751,100 shares of the company’s stock worth $33,358,000 after buying an additional 121,514 shares during the last quarter. Morgan Stanley increased its holdings in iTeos Therapeutics by 1.6% during the fourth quarter. Morgan Stanley now owns 846,859 shares of the company’s stock worth $16,539,000 after buying an additional 12,965 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in iTeos Therapeutics by 7.6% during the fourth quarter. JPMorgan Chase & Co. now owns 583,958 shares of the company’s stock worth $11,405,000 after buying an additional 41,053 shares during the last quarter. Hedge funds and other institutional investors own 97.16% of the company’s stock.
iTeos Therapeutics Stock Up 5.4 %
ITOS opened at $9.04 on Friday. The company has a market capitalization of $323.47 million, a price-to-earnings ratio of -11.30 and a beta of 1.22. The firm has a 50-day moving average price of $11.69 and a 200-day moving average price of $13.28. iTeos Therapeutics, Inc. has a twelve month low of $8.20 and a twelve month high of $23.00.
Insider Activity
In other news, insider Boxer Capital, Llc sold 350,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $16.26, for a total value of $5,691,000.00. Following the completion of the transaction, the insider now directly owns 1,804,058 shares in the company, valued at $29,333,983.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Matthew Gall acquired 5,000 shares of the business’s stock in a transaction dated Thursday, October 12th. The stock was bought at an average cost of $8.37 per share, for a total transaction of $41,850.00. Following the completion of the transaction, the chief financial officer now owns 19,429 shares of the company’s stock, valued at $162,620.73. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Boxer Capital, Llc sold 350,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $16.26, for a total transaction of $5,691,000.00. Following the completion of the transaction, the insider now owns 1,804,058 shares of the company’s stock, valued at $29,333,983.08. The disclosure for this sale can be found here. 10.20% of the stock is owned by company insiders.
Analyst Ratings Changes
A number of analysts recently issued reports on the stock. HC Wainwright decreased their price objective on shares of iTeos Therapeutics from $54.00 to $44.00 and set a “buy” rating for the company in a report on Wednesday, August 9th. Wedbush reiterated an “outperform” rating and issued a $33.00 target price on shares of iTeos Therapeutics in a research note on Tuesday, August 8th.
Check Out Our Latest Analysis on ITOS
iTeos Therapeutics Profile
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Featured Stories
- Five stocks we like better than iTeos Therapeutics
- How to Invest in Casino Stocks
- MarketBeat Week in Review – 10/9 – 10/13
- What is the Shanghai Stock Exchange Composite Index?
- What BlackRock’s Earnings Tell You About The Stock Market Tide
- Where to Find Earnings Call Transcripts
- Sociedad Quimica y Minera de Chile Well Positioned Lithium Stock
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
